Ambrosia Biosciences secured a $100 million oversubscribed Series B round to advance its oral obesity drug pipeline. The financing is earmarked for progression of the company’s lead oral small-molecule GLP-1 candidate into Phase I, alongside development of additional programs targeting GIP and amylin. The round is co-led by Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital, with participation from existing investors BVF Partners and Boulder Ventures. The deal arrives as oral obesity therapy expands post-FDA approval, increasing urgency for differentiated oral mechanisms and combinability. For the biotech ecosystem, the key implication is continued capital flow into oral cardiometabolic modalities beyond the injection-first incumbents, with investors underwriting platform work in structural biology and computational chemistry.